Info

SOFRADIM devotes at least 10% of its turnover to Research and Development. Made up of engineers, pharmaceutical and scientific Ph.Ds, the R&D team works closely with a large number of university based research laboratories as well as surgical departments of university and private hospitals. Due to its corporate commitment to research, SOFRADIM continues to increase its new technology development while it expands its new product offerings to the parietal and vascular surgery markets. In order to complete its current product ranges, SOFRADIM has developed new resorbable fixation devices, available in Europe 2nd quarter 2002.